Medical Oncology

, 34:21 | Cite as

RNAi-mediated knockdown of MCM7 gene on CML cells and its therapeutic potential for leukemia

  • Liang Tian
  • Juan Liu
  • Guo-Hua Xia
  • Bao-An ChenEmail author
Original Paper


MCM7 is one of the subunits of MCM2-7 complex, which is essential to DNA replication licensing and the control of cell cycle progression. It has been demonstrated that MCM7 participates in mRNA transcription and DNA damage regulation as well. MCM7 gene is found to be over-expressed in multiple cancers, but there are few reports about its effect in leukemia. Recent studies have proven that MCM7 expression has a relationship with diagnosis and prognosis, which has led to their potential clinical application as a marker for cancer screening. RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. It is a valuable research tool, which is widely used in cell culture and living organisms as well as in medicine recent years. It is indicated that RNAi application for targeting functional carcinogenic molecules, tumor resistance to chemotherapy and radiotherapy is required in cancer treatment. Gene products knockdown by RNAi technology exerts anti-proliferative and pro-apoptotic effects upon cell culture systems, animal models and in clinical trials in the most studies. In the present study, we found that MCM7 highly expressed in K562 cells rather than that in normal neutrophils. Thus, lentivirus-mediated shRNA targeting MCM7 was used to suppress its endogenous expression in K562 cells and develop a novel therapeutic strategy for leukemia.


MCM7 gene Lentivirus-mediated siRNA K562 cell Leukemia 



This study was funded by the Fundamental Research Funds for the Central Universities and Colleges and Universities in Jiangsu Province plans to graduate research and innovation 2014 (No. KYLX_0198); Key Medical Projects of Jiangsu Province (BL2014078).

Compliance with ethical standards

Conflict of interest


Ethics approval and consent to participate

All animal experiments were conducted in conformity with institutional guidelines for the care and use of laboratory animals, and protocols were approved by the National Science Council, Republic of China, and the Institutional Animal Care and Use Committee in Southeast University, China (NO. 2007-51).


  1. 1.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRefPubMedGoogle Scholar
  2. 2.
    Li JH, Wei Q, Liu T, et al. Phosphorylation of minichromosome maintenance protein 7(MCM7) by cyclin/cyclin-dependent kinase affects its function in cell cycle regulation. J Biol Chem. 2013;288:19715–25.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Luo J. Oncogenic activity of MCM7 transforming cluster. World J Clin Oncol. 2011;2:120–4.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Blow JJ, Dutta A. Preventing re-replication of chromosomal DNA. Nat Rev Mol Cell Biol. 2005;6:476–86.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Heike Y. Gene therapy for myeloid leukemia. Nihon Rinsho. 2009;67:1958–63.PubMedGoogle Scholar
  6. 6.
    Zhu ZX, Lin Z, Du J, et al. Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia. Mol Cell Biochem. 2014;390:75–84.CrossRefPubMedGoogle Scholar
  7. 7.
    Boudes PF. Gene therapy as a new treatment option for inherited monogenic diseases. Eur J Intern Med. 2014;25:31–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Kupferschmidt K. A lethal dose of RNA. Science. 2013;341:732–3.CrossRefPubMedGoogle Scholar
  9. 9.
    Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin Cancer Res. 2010;16(2):384–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Sclafani RA, Holzen TM. Cell cycle regulation of DNA replication. Annu Rev Genet. 2007;41:237–80.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dalton S, Whitbread L. Cell cycle-regulated nuclear import and export of Cdc47, a protein essential for initiation of DNA replication in budding yeast. Proc Natl Acad Sci USA. 1995;92:2514–8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chong JP, Thömmes P, Blow JJ. The role of MCM/P1 proteins in the licensing of DNA replication. Trends Biochem Sci. 1996;21:102–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Tye BK. MCM proteins in DNA replication. Annu Rev Biochem. 1999;68:649–86.CrossRefPubMedGoogle Scholar
  14. 14.
    Forsburg SL. Eukaryotic MCM proteins: beyond replication initiation. Microbiol Mol Biol Rev. 2004;68:109–31.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    You Z, Komamura Y, Ishimi Y. Biochemical analysis of the intrinsic Mcm4- Mcm6- Mcm7 DNA helicase activity. Mol Cell Biol. 1999;19:8003–15.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lee JK, Hurwitz J. Processive DNA helicase activity of the minichromosome maintenance proteins 4, 6, and 7 complex requires forked DNA structures. Proc Natl Acad Sci USA. 2001;98:54–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Foltman M, Evrin C, De Piccoli G, et al. Eukaryotic replisome components cooperate to process histones during chromosome replication. Cell Reports. 2013;3:892–904.CrossRefPubMedGoogle Scholar
  18. 18.
    Das M, Singh S, Pradhan S, et al. MCM Paradox: abundance of eukaryotic replicative helicases and genomic integrity. Mol Biol Int. 2014;2014:574850. doi: 10.1155/2014/574850.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lei M, Tye BK. Initiating DNA synthesis: from recruiting to activating the MCM complex. J Cell Sci. 2001;114:1447–54.PubMedGoogle Scholar
  20. 20.
    Tsuji T, Ficarro SB, Jiang W. Essential role of phosphorylation of MCM2 by Cdc7/Dbf4 in the initiation of DNA replication in mammalian cells. Mol Biol Cell. 2006;17:4459–72.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Tanaka S, Tak YS, Araki H. The role of CDK in the initiation step of DNA replication in eukaryotes. Cell Div. 2007;2:16.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    You Z, Ishimi Y, Masai H, et al. Roles of Mcm7 and Mcm4 subunits in the DNA helicase activity of the mouse Mcm4/6/7 complex. J Biol Chem. 2002;277:42471–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Cortez D, Glick G, Elledge SJ. Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases. Proc Natl Acad Sci USA. 2004;101:10078–83.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tsao CC, Geisen C, Abraham RT. Interaction between human MCM7 and Rad17 proteins is required for replication checkpoint signaling. EMBO J. 2004;23:4660–9.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Tan W, Li Y, Lim SG, et al. miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol. 2014;20:5962–72.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Yang H, Lan P, Hou Z, et al. Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma. Br J Cancer. 2015;112:112–21.CrossRefPubMedGoogle Scholar
  27. 27.
    Ishibashi Y, Kinugasa T, Akagi Y, et al. Minichromosome maintenance protein 7 is a risk factor for recurrence in patients with Dukes C colorectal cancer. Anticancer Res. 2014;34:4569–75.PubMedGoogle Scholar
  28. 28.
    Hua C, Zhao G, Li Y, Bie L. Minichromosome Maintenance (MCM) Family as potential diagnostic and prognostic tumor markers for human gliomas. BMC Cancer. 2014;14:526.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kang W, Tong JH, Chan AW, et al. MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function. Oncol Rep. 2014;31:2071–8.PubMedGoogle Scholar
  30. 30.
    Wu JZ, Lu P, Liu R, et al. Transcription regulation network analysis of MCF7 breast cancer cells exposed to estradiol. Asian Pac J Cancer Prev. 2012;13:3681–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Lee KS, Yuan YL, Kuriyama R, et al. Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol. 1995;15:7143–51.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    van de Weerdt BC, Medema RH. Polo-like kinases: a team in control of the division. Cell Cycle. 2006;5:853–64.CrossRefPubMedGoogle Scholar
  33. 33.
    Hyun SY, Hwan HI, Jang YJ. Polo-like kinase-1 in DNA damage response. BMB Rep. 2014;47:249–55.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Simizu SOH. Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines. Nat Cell Biol. 2000;2:852–4.CrossRefPubMedGoogle Scholar
  35. 35.
    Smith MR, Wilson ML, Hamanaka R, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun. 1997;234:397–405.CrossRefPubMedGoogle Scholar
  36. 36.
    Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia. 2009;23:1564–76.CrossRefPubMedGoogle Scholar
  37. 37.
    Gilmartin AG, Bleam MR, Richter MC, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 2009;69:6969–77.CrossRefPubMedGoogle Scholar
  38. 38.
    Tsvetkov L, Stern DF. Interaction of chromatin-associated PLK1 and Mcm7. J Biol Chem. 2005;280:11943–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Murugan RN, Park JE, Kim EH, et al. PLK1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Mol Cells. 2011;32:209–20.CrossRefPubMedGoogle Scholar
  40. 40.
    Schmit TL, Ledesma MC, Ahmad N. Modulating polo-like kinase 1 as a means for cancer chemoprevention. Pharm Res. 2010;27:989–98.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Cholewa BD, Liu X, Ahmad N. The role of polo-like kinase 1 in carcinogenesis: cause or consequence? Cancer Res. 2013;73:6848–55.CrossRefPubMedGoogle Scholar
  42. 42.
    Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2010;2:a001222.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Maclaine NJ, Hupp TR. The regulation of p53 by phosphorylation: a model for how distinct signals integrate into the p53 pathway. Aging (Albany NY). 2009;1:490–502.CrossRefGoogle Scholar
  44. 44.
    Ando K, Ozaki T, Yamamoto H, et al. Polo-like kinase 1 (PLK1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem. 2004;279:25549–61.CrossRefPubMedGoogle Scholar
  45. 45.
    Martin BT, Strebhardt K. Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle. 2006;5:2881–5.CrossRefPubMedGoogle Scholar
  46. 46.
    Degenhardt Y, Lampkin T. Targeting polo-like kinase in cancer therapy. Clin Cancer Res. 2010;16:384–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Hassan M, Watari H, AbuAlmaaty A, et al. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845. doi: 10.1155/2014/150845.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Mignard V, Lalier L, Paris F, et al. Bioactive lipids and the control of Bax pro-apoptotic activity. Cell Death Dis. 2014;5:e1266.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Galluzzi L, Morselli E, Kepp O, et al. Targeting p53 to mitochondria for cancer therapy. Cell Cycle. 2008;7:1949–55.CrossRefPubMedGoogle Scholar
  50. 50.
    Athar M, Back JH, Kopelovich L, et al. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009;486:95–102.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Wang F, Zhang W, Guo L, et al. Gambogic acid suppresses hypoxia-induced hypoxia-inducible factor-1a/vascular endothelial growth factor expression via inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein of rapamycin pathway in multiple myeloma cells. Cancer Sci. 2014;105:1063–70.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Liang Tian
    • 1
  • Juan Liu
    • 2
  • Guo-Hua Xia
    • 3
  • Bao-An Chen
    • 1
    Email author
  1. 1.Department of Hematology and Oncology, Medical School, Zhongda HospitalSoutheast UniversityNanjingChina
  2. 2.Department of Digestive System, Medical School, Zhongda HospitalSoutheast UniversityNanjingChina
  3. 3.Department of Clinical Laboratory, Medical SchoolSoutheast UniversityNanjingChina

Personalised recommendations